Lv4
710 积分 2022-10-15 加入
The Current Treatment Landscape of Malignant Pleural Mesothelioma and Future Directions
1个月前
已完结
Dual-targeted therapy with trastuzumab and lapatinib in treatment-refractory, KRAS codon 12/13 wild-type, HER2-positive metastatic colorectal cancer (HERACLES): a proof-of-concept, multicentre, open-label, phase 2 trial
1个月前
已完结
Trastuzumab deruxtecan in patients with solid tumours harbouring specific activating HER2 mutations (DESTINY-PanTumor01): an international, phase 2 study
1个月前
已完结
Trastuzumab deruxtecan in HER2-positive metastatic colorectal cancer: less is more?
1个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
1个月前
已完结
Trastuzumab deruxtecan in patients with HER2-positive advanced colorectal cancer (DESTINY-CRC02): primary results from a multicentre, randomised, phase 2 trial
1个月前
已完结
Diagnosis and treatment of human epidermal growth factor receptor 2-positive metastatic colorectal cancer: a systematic literature review
1个月前
已完结
美国胸科学会／欧洲呼吸学会（2013）特发性间质性肺炎的国际多学科分类解读
1个月前
已完结
Trastuzumab deruxtecan (DS-8201) in patients with HER2-expressing metastatic colorectal cancer (DESTINY-CRC01): a multicentre, open-label, phase 2 trial
1个月前
已完结
皖公网安备34019202002308
